376 related articles for article (PubMed ID: 22172527)
1. Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid-β cascade.
Belkacemi A; Ramassamy C
Free Radic Biol Med; 2012 Feb; 52(3):593-600. PubMed ID: 22172527
[TBL] [Abstract][Full Text] [Related]
2. Mouse models of Alzheimer's disease: the long and filamentous road.
Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
[TBL] [Abstract][Full Text] [Related]
3. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
4. Twenty Years of Presenilins--Important Proteins in Health and Disease.
Walter J
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S41-8. PubMed ID: 26605647
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
7. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
Kuzuhara S
Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
[TBL] [Abstract][Full Text] [Related]
8. Axonopathy Likely Initiates Neuropathological Processes Via a Mechanism of Axonal Leakage in Alzheimer's Mouse Models.
Gao G; He J; Luo Y; Sun Y; Zhou Y; Zhang J; Xing Y; Dai J
Curr Mol Med; 2019; 19(3):183-195. PubMed ID: 30961496
[TBL] [Abstract][Full Text] [Related]
9. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
[TBL] [Abstract][Full Text] [Related]
10. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress accelerates amyloid deposition and memory impairment in a double-transgenic mouse model of Alzheimer's disease.
Kanamaru T; Kamimura N; Yokota T; Iuchi K; Nishimaki K; Takami S; Akashiba H; Shitaka Y; Katsura K; Kimura K; Ohta S
Neurosci Lett; 2015 Feb; 587():126-31. PubMed ID: 25529196
[TBL] [Abstract][Full Text] [Related]
12. Selecting a mouse model of Alzheimer's disease.
Chin J
Methods Mol Biol; 2011; 670():169-89. PubMed ID: 20967591
[TBL] [Abstract][Full Text] [Related]
13. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.
Eckert A; Schulz KL; Rhein V; Götz J
Mol Neurobiol; 2010 Jun; 41(2-3):107-14. PubMed ID: 20217279
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Serum Exosomes from a Transgenic Mouse Model of Alzheimer's Disease.
Rosas-Hernandez H; Cuevas E; Raymick JB; Robinson BL; Ali SF; Hanig J; Sarkar S
Curr Alzheimer Res; 2019; 16(5):388-395. PubMed ID: 30907317
[TBL] [Abstract][Full Text] [Related]
15. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease.
Matsuoka Y; Picciano M; La Francois J; Duff K
Neuroscience; 2001; 104(3):609-13. PubMed ID: 11440793
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Chu J; Lauretti E; Craige CP; Praticò D
J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
[TBL] [Abstract][Full Text] [Related]
18. Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse.
Ontiveros-Torres MÁ; Labra-Barrios ML; Díaz-Cintra S; Aguilar-Vázquez AR; Moreno-Campuzano S; Flores-Rodríguez P; Luna-Herrera C; Mena R; Perry G; Florán-Garduño B; Luna-Muñoz J; Luna-Arias JP
J Alzheimers Dis; 2016 Mar; 52(1):243-69. PubMed ID: 27031470
[TBL] [Abstract][Full Text] [Related]
19. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment.
Butterfield DA; Reed T; Newman SF; Sultana R
Free Radic Biol Med; 2007 Sep; 43(5):658-77. PubMed ID: 17664130
[TBL] [Abstract][Full Text] [Related]
20. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
